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Abstract 
The production of megakaryocytes (MKs) – the precursors of blood platelets – from human pluripotent stem cells 
(hPSCs) offers exciting clinical opportunities for transfusion medicine. We describe an original approach for the large 
scale generation of MKs in chemically defined conditions using a forward programming strategy relying on the 
concurrent exogenous expression of 3 transcription factors: GATA1, FLI1 and TAL1. The forward programmed MKs 
proliferate and differentiate in culture for several months with MK purity over 90% reaching up to 2x105 mature MKs 
per input hPSC. Functional platelets are generated throughout the culture allowing the prospective collection of 
several transfusion units from as few as one million starting hPSCs. The high cell purity and yield achieved by MK 
forward programming, combined with efficient cryopreservation and GMP compatible culture, make this approach 
eminently suitable to both in vitro production of platelets for transfusion and basic research in MK and platelet 
biology. 
 
Key words: human pluripotent stem cell; megakaryocyte; transcription factor; forward programming; platelets. 
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INTRODUCTION 
Megakaryocytes (MKs) generate blood platelets whose primary role is to stop hemorrhages via localized clot 
formation at the site of vessel injury 1,2. MKs are polyploid cells derived from hematopoietic stem cells residing in the 
bone marrow where they represent only 0.01% of the total nucleated blood cells. By extension of cytoplasmic 
protrusions through bone marrow sinusoids, they release daily approximately 1x1011 platelets into the blood stream 
in order to sustain the count of short-lived (7-10 days) circulating platelets between 150-450x109 per litre of blood 
3,4. A decrease in platelet number, or thrombocytopenia, may occur following bone marrow failure (inherited or 
acquired, such as post-cancer treatment) or severe peripheral bleeding after trauma or surgery, and potentially leads 
to life-threatening hemorrhages. Currently, prophylactic and therapeutic treatment essentially relies on transfusion 
of ABO and Rhesus-D matched platelet concentrates - at >2.4x1011 platelets per unit - from voluntary donations 5,6. 
Recently, the increase in high-dose cancer therapy, advanced surgical procedures and the ageing population has led 
to a rising demand for platelets with over 4.5 million platelet units transfused per year in Europe and the United 
States 7. In addition, platelet transfusion refractoriness in HLA class I alloimmunized chronically transfused patients 
and multiparous women necessitates the special provision of matched platelet units sourced from a small pool of 
genotyped recallable donors 8. Altogether, the dependence on donations combined with the limited shelf life of 
platelet concentrates (5-7 days) represents a logistical, financial and biosafety challenge for health organizations 
worldwide. 
Human pluripotent stem cells (hPSCs) – including embryonic stem cells (hESCs) derived from embryos and induced 
pluripotent stem cells (hiPSCs) generated from post-natal somatic cells - can be maintained in vitro for prolonged 
periods while retaining the capacity to differentiate towards virtually any cell type upon adequate stimulation 9-11. 
Therefore, they offer huge opportunities for basic research and clinical applications 12. The production of platelets in 
vitro from genetically defined hPSC lines could revolutionize transfusion medicine by providing a controllable source 
of platelets 13. Moreover, platelets are anucleate and do not proliferate which means they can be irradiated before 
transfusion. This provides a marked safety advantage over other hPSC-derived therapeutic cells which can 
potentially retain oncogenic cell fractions 14. However, in vitro systems for the production of large amounts of MKs 
and subsequent platelet release to match the needs for making transfusion units still require considerable 
optimization.  
Our work describes a novel approach for generating large quantities of functional MKs from hPSCs with unique 
advantages for clinical development. Existing protocols have so far relied on external signals provided by cytokines or 
stromal cells to mimic embryonic development in vitro and thus direct sequential differentiation of hPSCs into MKs, 
a process designated as “directed differentiation” (DD) 15-20. While mature MKs showing functional platelet release 
are produced, this strategy has been limited by the relatively low number of MKs generated or by the complex 
genetic modifications and clonal selection required to immortalize MKs post differentiation. Urged by the recent 
discoveries on the plasticity of cell identities controlled by limited sets of transcription factors (TFs) 21, we adopted a 
radically different approach for the generation of MKs by exploring the potential of exogenous TFs to drive the 
differentiation process from hPSCs, a strategy called “forward programming” (FOP). Proceeding from a methodically 
curated list of candidate genes, we discovered that the combination of GATA1-FLI1-TAL1 uniquely promoted highly 
efficient MK-FOP from an array of hPSC lines in chemically defined conditions. Critically, the forward programmed 
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MKs (fopMKs) matured into platelet-producing cells that could be cryopreserved, maintained and amplified in vitro 
for over 90 days showing an average yield of 200,000 MKs per input hPSC. This unprecedented efficiency combined 
with minimal cell manipulation and low cytokine requirements makes MK-FOP a promising platform for basic 
research as well as future clinical applications in the field of transfusion medicine. 
 
RESULTS 
GATA1-FLI1-TAL1 combination induces hPSC to MK commitment. Based on the knowledge that cooperative binding 
of TFs to target sites can activate gene expression in repressed chromatin 22, we hypothesized that MK-specific TFs 
forming complexes able to interact with chromatin remodelers would be able to rewire the hPSC gene regulatory 
network to induce MK-FOP. We compared TF expression in the H9 hESC line and cord blood-derived megakaryocytes 
(cbMKs) 23 and narrowed down to a list of 46 TF candidates subsequently ranked based on differential gene 
expression level and reported protein interactions between candidates and epigenome modifiers using VisANT 24 
(Supplementary Fig.1 and Methods for details). Nine TFs from the top 20 candidates were individually cloned into a 
lentiviral vector backbone under the control of an EF1α promoter to assess their MKFOP potential (Fig. 1a). 
H9 cells were transduced concurrently with equal amounts of each lentiviral vector and subsequently maintained in 
hPSC medium (FGF2 + Activin-A) for 2 days followed by MK medium (TPO + SCF) for a further 5 days. The 
transduction efficiency measured with a GFP reporter vector was 60.3±5.6% in these conditions (n=4). Transduction 
with the 9 TFs generated a well-defined population of cells expressing CD41a (integrin alpha-IIb: ITGA2B) on day 7 
(1.1±0.6%; Fig. 1b). In an attempt to identify the critical TFs responsible for the generation of this population 
expressing the marker typically associated with MK lineage commitment, CD41a+ cells were sorted and transgene 
expression measured by RT-qPCR. Intriguingly, we detected a striking bias for GATA1, FLI1 and TAL1 (hereafter “3-
TFs”) transgene expression in the CD41a+ population compared to its negative counterpart which suggested their 
instrumental role in the acquisition of the CD41a phenotype (Fig. 1b). Accordingly, the 3-TF combination tested in 
two hiPSC lines generated more CD41a+ cells compared to all 9-TFs together demonstrating its superior efficiency 
(2.5±0.04% vs. 0.2±0.04% respectively; Fig. 1c). We assessed all permutations of the 3-TFs and showed that the 
maximum CD41a+ cell yield was achieved upon concurrent transduction of the 3-TFs which also correlated with a 
higher clonogenic potential (Fig. 1d and Supplementary Fig. 2a). Importantly, no CD41a+ cells were detected after 
transduction with a GFP control vector demonstrating that culture conditions were not inductive per se (Fig. 1d). 
Finally, we combined the 3-TFs using a single lentiviral vector carrying a polycistronic expression cassette encoding 
for the 3-TFs and a GFP reporter. Virtually all GFP-positive cells differentiated into CD41a+ cells by day 7, confirming 
the efficacy of the 3-TFs in inducing MK-FOP (Supplementary Fig. 2b).  
Additional analyses confirmed that the emerging CD41a+ population at day 7 truly represented early MK lineage 
commitment. We first showed that the expression of key MK genes including MPL (coding for the TPO receptor), the 
TFs ZFPM1, RUNX1, NFE2 as well as the endogenous expression of GATA1, FLI1 and TAL1 were specifically induced in 
the CD41a+ cell population (Fig. 1e). Moreover, the MK clonogenic potential was exclusively retained in the CD41a+ 
cell population which further developed to mature MK colonies expressing CD42b (glycoprotein-Ib: GPIBA) 
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functionally demonstrating MK commitment (Fig. 1f-g). Altogether, we thereby identified GATA1, FLI1 and TAL1 as a 
minimal and sufficient combination of TFs to induce the formation of MK precursors from hPSCs. 
 
Chemically defined MK-FOP generates high purity MK cultures. To facilitate transfer to the clinic, we developed a 
chemically defined xeno-free 3-TF MK-FOP protocol. Induction of mesoderm commitment from hiPSCs by a 2 day 
exposure to FGF2, BMP4 and LY-294002 25 significantly increased the percentage of CD41a+ cells at day 7 compared 
to pluripotency maintenance conditions (5.4±1.6-fold increase; Supplementary Fig. 3a). Next, we assessed the 
benefit of using forced aggregation embryoid body (EB) formation instead of the base 2-D culture. When coupled 
with mesoderm-inducing conditions, EB culture further improved the yield of CD41a+ cells at day 7 (5.2±0.9-fold 
increase; Supplementary Fig. 3b). The EB culture had the additional advantage of providing a standardized quantity 
of input cells thereby conferring reproducibility. The final protocol combined lentiviral transduction with EB 
formation over the first 24 hours with mesoderm induction for the first 2 days. This protocol allowed consistent 
transduction efficiencies amongst hiPSC lines (68.2±4.1% using a single GFP control vector, n=11 using 3 hiPSC lines), 
resulting in 22% co-transduction efficiency as estimated using reporter vectors (Supplementary Fig.3c). As MK 
maturation was not optimally sustained in the low-adherence EB culture setting, we included a single cell 
dissociation step which gave an optimal MK yield when performed at day 10 post-transduction (Supplementary Fig. 
3d) followed by a further 10 day culture in medium containing TPO and IL1β routinely used for cbMK differentiation 
26. The optimized MK-FOP protocol using xeno-free GMP-grade basal medium and recombinant cytokines is depicted 
in Fig. 2a. 
We observed a gradual increase in CD41a+ cells from day 4 post-transduction followed by the acquisition of the 
mature MK marker CD42a (glycoprotein IX:GP9, component of the Von Willebrand platelet receptor complex) from 
day 6 onwards mimicking cbMK differentiation (Fig. 2b and Supplementary Fig. 3e). Critically, using two different 
hiPSC lines, MK-FOP consistently achieved MK lineage purity (>95% CD41a+ cells) by day 15 post-transduction with 
more than 50% CD42a+ mature MKs by day 20 (Fig. 2b). A robust cell expansion during the single cell culture step led 
to the generation of large quantities of MKs with up to 28.4±7.8-fold increase relative to the hiPSC input at day 20 
(iPSC#1, n=14; Fig. 2c). Interestingly, MK-FOP achieved significantly higher cell yields compared to a standard MK-DD 
approach 27, producing in our hands on average 26.3 and 11.7 times more mature MKs from the hiPSC lines #1 and 
#2 respectively (Fig. 2c). In addition, the MK purity obtained by MK-FOP was significantly higher than MK-DD 
(97.7±0.8% vs. 21.3±2.9% respectively; Supplementary Fig. 3f). 
To further assess the MK identity of FOP cells, day 20 fopMKs were compared to day 10 cbMKs as a benchmark. At 
this stage, both cultures show similar MK maturity (50-60% CD42a+ cells; Fig. 2b and Supplementary Fig. 3e). The 
key platelet surface receptors for fibrinogen [αIIb-β3], Von Willebrand Factor [gpIb-V-IX] and collagen [gpVI] were 
readily detected in both cultures (Fig. 2d). Morphologically, fopMK cultures displayed a typical mix of 
megakaryoblasts with large peripheral nuclei and mature MKs with increased cytoplasmic volume and frequent 
polyploid cells similarly to cbMK cultures (Fig. 2e-f). In accordance with published results for in vitro derived neonate 
and hPSC MKs 17,28, the cell ploidy remained low on average and was comparable for both fopMKs and cbMKs (<2% 
8N cells; Supplementary Fig. 3g). Analysis of the fopMK ultrastructure by electron microscopy showed lobulated 
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nuclei, developing demarcation membrane system (cytoplasmic cell membrane supply for platelet release), 
cytoplasmic multi-vesicular bodies (precursors to platelet granules) and mature granules (Fig. 2g). We confirmed by 
confocal microscopy that major alpha-granule proteins (P-selectin, thrombospondin, fibrinogen and vWF) were 
indeed correctly expressed and patterned in fopMKs (Fig. 2h). Importantly, the total expression level of the 3-TFs in 
fopMKs – as sum of transgenic and endogenous expression - was not significantly different from cbMKs 
(Supplementary Fig. 3h). Collectively, these data demonstrate the efficient production and maturation of MKs 
derived by forward programming in xeno-free chemically-defined conditions. 
 
MK-FOP produces expandable and cryobankable mature MK cultures. We found that fopMKs could be maintained 
in culture and kept expanding for an extended period of up to 60 days in the TPO+IL1β condition described above 
(Supplementary Fig. 4a-c). The expression of KIT (the receptor for stem cell factor (SCF), an hematopoietic 
progenitor pleiotropic cytokine) on a fraction of the cells suggested the persistence of a progenitor population in 
MK-FOP cultures (Supplementary Fig. 4d). This led us to test the continuous supplementation with SCF (50ng/ml) - 
instead of IL1β originally used through the second step of culture - in an attempt to improve further long-term 
maintenance.  In addition, we reasoned that the high TPO level (100ng/ml) may not be required in the MK-FOP 
context where differentiation was sustained internally by expression of the 3-TFs, and indeed high TPO may be 
responsible for precocious exhaustion of MK-FOP cultures by over stimulation of differentiation. Consequently, we 
tested a lower TPO concentration (20ng/ml) in combination with SCF through the second step of MK-FOP (Fig. 3a). In 
these conditions, we were able to maintain fopMKs in culture with steady proliferation for at least 90 days, achieving 
close to an average 200,000 MK yield per input hiPSC (1.94±1.59x105, n=7 for hiPSC#1 and #3 cumulatively; Fig. 3b). 
This was in striking contrast with the maximum 1,300 MK fold increase, earlier loss of CD42a expression and cell 
viability in long term culture using the original high TPO and IL1β condition (Supplementary Fig. 4a-c). The MKs 
harvested from optimized long-term cultures (>30 days, defined thereafter as LT-fopMKs) maintained a purity of 
over 90% CD41a+ cells with levels of CD42a expression >60% (Fig. 3c-e) and an increase in late maturation markers 
like GPVI (Supplementary Fig. 4e). The LT-fopMK cultures contained a mixed population of small megakaryoblasts 
growing in loose clusters representing the actively proliferating cell fraction together with larger polyploid MKs (Fig. 
3f-h). Critically, LT-fopMKs were successfully frozen over a day 21-70 timeframe and subsequently recovered for 
further culture and expansion allowing cryobanking of fopMK batches (Supplementary Fig. 4f). 
We found that LT-fopMK cultures were not immortalized but finite with the longest iPSC#1 and iPSC#3 cultures kept 
for 120 and 132 days, culminating respectively in 17 million and 800,000 MK fold increases (n=4/5 biological 
replicate respectively; Supplementary Fig. 4g). Beyond day 90, most LT-fopMK cultures showed a drastic loss of cell 
viability (Supplementary Fig. 4h) associated with a steady decrease of clonogenic potential and of CD34+ 
hematopoietic progenitor content (Supplementary Fig. 4i-j). At the population level, the average expression of the 
3-TFs (sum of endogenous and transgenic expression) in LT-fopMK cultures was maintained in a close range to day 
10 cbMKs (Fig. 3i). Together, we showed the 3-TF driven MK-FOP generated a highly proliferative albeit exhaustible 
progenitor pool sustaining the expansion of mature MKs in vitro for over 3 months. 
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Genome-wide analysis confirms long-term MK identity. We analyzed the whole genome microarray expression data 
of MKs derived in vitro by different protocols and from different stem cell sources: by FOP or DD from hiPSCs 
(fopMKs, LT-fopMKs and ddMKs) and from cord blood primary hematopoietic stem cells (cbMKs), all samples with 
purity greater than 95% CD41a+ and 80% CD42a+ cells. 
First, enrichment analysis using hyperG test (fdr ≤5%) of Gene Ontology (GO) terms from up-regulated genes versus 
undifferentiated hiPSC confirmed that MK-FOP efficiently induced the MK phenotype with top biological processes in 
fopMKs and LT-fopMKs related to hemostasis/platelet GO terms as was the case for ddMKs and cbMKs (Fig. 4a). This 
was mirrored by a depletion in differentiation/morphogenesis GO term associated genes indicating appropriate 
down-regulation of pluripotency features (Fig. 4a). Moreover, the gene set enrichment analysis (GSEA 29) against a 
panel of blood cells (cbMKs versus other blood cells from Haematlas 23; n=4 and 46 respectively) showed specific 
enrichment of MK-specific genes in the list of genes upregulated in fopMKs further demonstrating the acquisition of 
a genuine MK phenotype (Normalised Enrichment Score NES=1.25, fdr=21%; Fig.4b). The highly similar expression 
profiles obtained from 2 distinct hiPSC lines demonstrates the inter-line qualitative reproducibility of MK-FOP 
(r2=0.998 for iPSC#1 and #2; Fig.4c). 
Differential expression (DE) analysis comparing hiPSC-derived MKs to cbMKs revealed a number of DE genes that 
were (in accordance with the MK phenotype acquired by fopMKs) not related to hemostasis/platelet-related 
biological processes (503 common, 2667 total; ≥2 fold-change and FDR≤5% cutoff; Fig. 4d). Hierarchical clustering 
distinguished the four MK groups while showing a separate cluster encompassing the hiPSC-derived MKs (i.e. 
fopMKs, LT-fopMKs and ddMKs) distinct from cbMKs indicative of an intrinsic difference resulting from their hPSC 
provenance, as previously described 30 (Fig. 4e). Interestingly, while confirming a shared hiPSC-MK identity distinct 
from cbMKs, the principal component analysis (PCA) indicated that LT-fopMKs clustered closer to cbMKs than 
fopMKs and ddMKs (Fig. 4f).30  Altogether, the whole genome expression analysis validated the acquisition by MK-
FOP of a genuine MK phenotype that was effectively maintained throughout long-term culture. 
 
In vitro production of functional platelets by fopMKs. Mature MKs produce platelets by a process of proplatelet 
formation whereby MKs extend cytoplasmic protrusions into the bone marrow blood stream 31. These protrusions 
contain multiple branching points and bulbous ends with active accumulation of granules into the end processes that 
represent the nascent platelets which then mature further in the circulation. In culture, fopMKs formed proplatelets 
containing P-selectin positive α-granules (Fig. 5a-b and Supplementary movies 1-2). For further analyses, in vitro 
platelet production was maximized using a static co-culture system with the murine C3H10T1/2 feeder cell line as 
previously described 27. Electron microscopy showed that platelets produced in vitro from fopMKs and cbMKs, while 
heterogeneous in quality reflecting the current limitations of 2-dimensional static cultures, showed the typical 
platelet ultrastructure notably including high alpha-granule content (Fig. 5c). We further used flow cytometry for the 
quantitative measurement of in vitro platelet production from fopMKs, strictly defining platelets as CD41a+/CD42a+ 
particles of human platelet size (fig. 5d). A significant increase in platelet production from LT-fopMKs versus day 20 
fopMKs was observed matching platelet release from cbMKs (5±0.2 vs. 0.8±0.2 platelets per MK at day 90 and day 20 
respectively; Fig. 5e). The platelet production rate was similar amongst fopMKs derived from different hiPSC lines 
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(hiPSC#1-4; Supplementary Fig.5a). In vitro platelets showed surface expression of the main thrombocyte receptors 
including the GPIIb/IIIa complex (fibrinogen receptor), GPIb and GPIX (Von Willebrand factor receptor), GPIIa and 
GPVI (collagen receptors), some of them with a decreased intensity compared to donor platelets which has been 
previously described and likely originated from the static 37°C in vitro culture conditions used for production 
(Supplementary Fig. 5b) 20,32. The fopMK platelets showed a normal mean volume on a clinical Sysmex blood 
analyzer (8.6 ±0.7fL, n=2, iPSC#1 and #5; Fig.5 f), and interestingly an increased immature platelet fraction compared 
to normal circulating blood (11.6 ±3% vs. 4±1% respectively; Fig. 5g). Eventually, we assessed fopMK platelet survival 
in vivo in immunodeficient NSG mice with further splenic macrophage depletion to allow human platelet 
maintenance in the circulation 33. The fopMK platelets were readily detected in the circulation for several hours 
while showing a shorter half-life than primary donor platelets (7.1 ±0.8h vs. 19.7 ±2.2h respectively; Fig. 5h), a result 
which was very similar to previously published data (7.5 and 18.3h respectively) 19 and probably biased by the 
limitations of the current static in vitro production systems for the generation of homogenous populations of 
genuine resting platelets endowed with longer circulation half-life. To further distinguish functional platelets from 
the heterogeneous in vitro produced pool, we used Calcein-AM as a marker of platelet viability and membrane 
integrity 34. The proportion of Calcein-AM positive platelets within fopMK and cbMK- derived platelet harvest was 
32.4±0.8% (n=3; iPSC#1, #5) and 40.1±3.6% respectively (n=3) and defined a phenotypically more homogenous 
CD41a+/CD42a+ platelet population similar to control blood (Supplementary fig. 5c). Hereafter, in vitro generated 
platelets were identified using Calcein-AM staining to compare their function to donor derived platelets. 
In order to fulfil their hemostatic role, platelets must be able to sequentially adhere to damaged vessels (using 
collagen and other extra-cellular matrix receptors), increase their surface by spreading (by active remodeling of their 
cytoskeleton), build-up the thrombus by aggregation of other platelets (through fibrinogen binding) and eventually 
amplify the hemostatic response through degranulation (granule content release to the surface) 35. We first 
compared adhesion to fibrinogen using a quantitative flow cytometry assay 36. Similarly to platelets generated in 
vitro from cbMKs, an increased adhesion to fibrinogen was observed for fopMK-derived platelets as compared to 
blood platelets (Fig. 6a). This distinction may be inherent to the platelet harvest methodology or originate from 
intrinsic developmental biological differences of hiPSC and neonates platelets compared to adult blood platelets 37. 
We further showed that fopMK-derived platelets spread efficiently upon contact with fibrinogen presenting typical 
tubulin cytoskeletal reorganization (Fig. 6b). We then used a flow cytometry approach to quantitatively measure 
agonist-induced platelet aggregation 38 (Fig. 6c). We showed that in response to agonist stimulation (a combination 
of ADP and TRAP), fopMK-derived platelets efficiently aggregated with fresh blood platelets as well as between 
themselves with no significant difference in aggregation potential as compared to blood platelets (Fig. 6d-e). 
Eventually, we performed thrombus formation in vitro under physiological shear stress as a high level assay of 
integrated platelet functions. In order to mimic a transfusion setting, we introduced a defined amount of Calcein-AM 
labelled in vitro produced platelets or blood platelets from a transfusion unit into normal or thrombocytopenic fresh 
human blood (platelet count <50x109/L; spiked platelets at 10x109/L; Supplementary movies 3-4). When exposed to 
collagen under arterial shear rates (1,600s-1), fopMK-derived platelets took part in clot formation similarly to 
platelets from a concentrate unit (Fig. 6f-g). We further observed an increase in the contribution of fopMK platelets 
to the thrombi in the context of thrombocytopenic blood (Fig.6 f-g and Supplementary Fig. 5d). Furthermore, P-
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selectin surface expression was observed in the platelets participating in the thrombi, thereby proving adequate 
degranulation of activated fopMK platelets (Supplementary Fig. 5e). The validation of fopMK platelet function was 
ultimately addressed in vivo using intravital microscopy and laser injury induced thrombus formation in the 
cremaster vasculature of NSG mice 39. The transfusion of 5E+7 Calcein-AM labelled platelets into mouse circulation 
allowed the visualization of human platelet integration into thrombi with comparable efficiencies between donor 
and fopMK platelets (1.5 ±0.2 and 1.4 ±0.2 platelets per 100um2 thrombus area respectively, n=16/12; Fig. 6h-i ). 
Strikingly, in vitro produced fopMK platelets showed active participation in clot formation with visible sequential 
rolling, binding, thrombus surface surveying and spreading (Supplementary movies 5-6). 
While current systems for in vitro platelet production from cultured MKs can be further optimized beyond the 2-
dimensional static approach used here, platelets produced in vitro from fopMKs were nevertheless functionally 
similar to donor-derived platelets across a range of assays, thereby affirming their suitability and promise for a host 
of regenerative medicine research and therapeutic applications.  
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DISCUSSION 
We describe here forward programming, a novel approach for the chemically-defined large-scale production of MKs 
from hiPSCs. We drive MK development by the combined ectopic expression of three TFs: GATA1, FLI1 and TAL1. 
These 3 TFs have well-documented roles in hematopoiesis, especially in the maintenance of early hematopoietic 
progenitors, red blood cell and megakaryocyte differentiation 40-44. Forced expression of GATA1 or TAL1 alone in 
hematopoietic progenitors has been shown to bias differentiation towards MK and erythroid fates 45,46, while FLI1 
cooperates with GATA1 to enable MK maturation 47. In addition, TAL1 and FLI1 play an earlier role in the 
specification of the hematopoietic program during vertebrate embryonic development 48,49. Accordingly, exogenous 
expression of TAL1 in hESCs has been reported to promote hematopoiesis and megakaryopoiesis 50,51. More recently, 
the combinatorial expression of TAL1 with GATA2 was found to induce an hemogenic endothelial phenotype biased 
towards erythro-megakaryocytic differentiation from hPSCs 52. Nevertheless, the MK-FOP approach described here 
involving co-expression of the 3-TFs GATA1, FLI1 and TAL1 is unprecedented in regard to its efficiency in rapidly 
imposing MK progenitor identity to hPSCs in very stringent MK specific culture conditions. The high hierarchical 
status of the 3-TFs within the MK gene regulatory network, already supported by previously published gene 
interaction network and ChIP-sequencing data in primary human MKs 26,53 (Supplementary Fig.2 c), is now 
functionally confirmed in human cells by the efficiency of the MK-FOP approach. 
It remains to be demonstrated how closely the 3-TF programming recapitulates normal hematopoietic development 
from hPSCs. Current data indicate that mesoderm commitment is strongly beneficial to MK-FOP, consistent with the 
normal ontogeny of blood cells in the embryo. Intriguingly, we observed an early expression of hemogenic 
endothelium markers (FLK1, CD34 and VE-Cadherin) from day 2 of programming which was intermingled with 
expression of the megakaryocyte commitment marker CD41a and quickly followed by a marker of blood 
commitment with the increasing concurrent CD43 expression from day3 onwards (Supplementary Fig.6). The 
progressive decrease of endothelial populations associated with a steady TPO dependent growth of CD41a+ cells 
from day 4, as well as the absence of monocyte/granulocyte colonies in clonogenic assays, indicates an early 
commitment to MK fate (Supplementary Fig.6). Taken together, these observations suggest that overexpression of 
the 3-TFs in hPSCs may at least partially recapitulate key steps of the blood ontogeny with a contracted hemogenic 
endothelium phase and early enforcement of MK identity. Controllable and traceable 3-TF expression systems 
combined with molecular analysis at the single cell level will be necessary to further decipher the precise molecular 
mechanisms governing MK-FOP. 
There is high biotechnological significance in our ability to maintain the forward programmed cells in long-term 
cultures and expand them over time whilst preserving MK purity, markers of maturity and platelet production. This 
TPO- and SCF-dependent cellular proliferation persisted for an extended but not indefinite timeframe (90-134 days) 
and is presumably sustained by non-transformed early MK-biased progenitors (<1% by CFU assays) able to 
proliferate and differentiate further towards mature MKs. In this respect the LT-fopMK culture appears different in 
nature to the recently described expandable MK cell lines obtained from hPSCs by sequential ectopic introduction of 
MYC, BMI1 and BCL-XL into MK committed cells 20. The generation of these MK cell lines notably requires the precise 
control of MYC expression levels and subsequent silencing of those 3 overexpressed genes in order to achieve full 
MK maturation. The complex genetic modifications involved and the limited success rate of immortalized MK line 
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derivation - involving manual screening and clonal selection - along with the initial generation of blood progenitors in 
undefined conditions are limitations of that protocol for both research and clinical development. MK-FOP did not 
produce an immortalized MK progenitor and did not require manipulation of gene expression levels to produce fully 
mature MKs. Interestingly, MK lineage biased self-renewing progenitors have been recently identified in the 
hematopoietic stem cell phenotypic compartment of the bone marrow 54. Further investigations are needed to 
understand the full nature and the 3-TF driven molecular mechanisms underpinning the generation of this long-term 
expanding MK progenitor. 
Recently, another approach has been published that allows the expansion of MK progenitors derived from PSCs 55. In 
contrast with MK-FOP, that system is based on the artificially controlled downregulation of GATA1 in hematopoietic 
progenitors allowing MK progenitor expansion and its restoration to enable subsequent MK maturation. The 
approach, which was developed with mouse ESCs, has yet to be demonstrated to work in human cells. In addition, 
the authors did not show efficient platelet production from these MKs in vitro, instead choosing an adoptive transfer 
of MKs into recipient mice. The injection of nucleated cells derived from human pluripotent stem cells would raise 
crucial issues of potential tumorigenicity that could constrain future clinical use. 
The quantitative functional platelet data collected here proved that platelets derived from fopMKs in vitro are 
endowed with major platelet functions allowing efficient thrombus formation as shown in previous studies 19,20. 
Although abnormalities in key TFs for the MK lineage can lead to abnormal platelet function 43, the preservation of 
fopMK platelet function is consistent with the fact that the overall expression levels of the 3-TFs is controlled  
throughout the programming progression and similar to cbMKs. The remaining bottleneck for application to 
transfusion medicine is the optimization of platelet generation in vitro: this presently remains on average 1,000-fold 
lower than the in vivo platelet yield per MK and is accompanied by issues regarding the purity of the final product 
where functional platelets represent only a fraction of the platelet size particles in the whole harvest 19,20,56. In this 
study, which focuses on the production of the MKs themselves, we have used a previously published platelet 
production system based on co-culture with a mouse stromal cell line 27,57. Our findings clearly confer an impetus to 
achieve further progress using newly-developed 3D laminar flow systems and bone marrow mimicking scaffolds 58-60 
by providing ample quantities of functional MKs from hPSCs using a simplified chemically defined protocol amenable 
to the generation of a clinical product. 
In conclusion, our study demonstrates the feasibility of a forward programming approach to generate mature 
functional MKs from human PSCs that significantly transcends available directed differentiation protocols through a 
unique combination of key achievements. First, the methodology results in a very high cell yield and MK purity using 
fully chemically defined xeno-free culture conditions. To put this in the clinical context, the long-term culture 
expansion allows a cumulative production of 2x1011 MKs releasing 1x1012 platelets – the equivalent of 3 transfusion 
units - starting from only one million hiPSCs. Moreover, the minimal cell handling and cytokine requirements, the 
cryopreservation of fopMKs enabling cell banking and future stock management and the successful differentiation of 
an array of hPSC lines with qualitative reproducibility are additional critical strengths of the MK-FOP approach for 
future manufacturing of platelets for human therapeutic applications. The effectiveness and versatility of MK-FOP 
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opens new avenues for future basic research and functional studies on novel MK and platelet genes as well as 
disease modelling using hiPSCs 53,61,62. 
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METHODS 
Human pluripotent stem cell (hPSC) culture. The H9 human embryonic stem cell (hESC) line (WiCell; passages 75-95) 
and induced pluripotent stem cell (hiPSC) lines (iPSC#1-5; A1ATD1, BBHX8, A1ATD1-c, S4-SF5 and FFDK1 respectively, 
p30-50) were cultivated as clumps in a chemically defined medium (CDM) containing recombinant human FGF2 and 
Activin A (15ng/ml each, internal) on feeder-free gelatin or vitronectin coated wells as previously described 63. All 
hiPSC lines were obtained from the Cambridge Biomedical Research Centre iPSC Core Facility and have been derived 
from adult dermal fibroblasts using integrative murine retroviral vectors (iPSC#1-2), cytoplasmic Sendai viral vectors 
(iPSC#3-4) or episomal vectors (iPSC#5) expressing the human OCT4, SOX2, KLF4 and MYC reprogramming factors. 
Selection of transcription factor candidates. We performed a differential gene expression analysis focused on DNA 
binding protein coding genes (PANTHER Classification System) from whole genome expression data generated using 
the H9 hESC line (internal data, Illumina HumanWG-6 v3) and human cord blood derived MKs 23. The list of 116 MK 
specific genes generated was further refined by removal of 21 histone coding genes and addition of 6 candidates 
based on previous knowledge of their role in megakaryopoiesis (Supplementary Fig.1a). Using the VisANT web-
based software24, the resulting 101 candidate genes were subsequently ranked based on number of 1) internal 
protein interactions, 2) interaction with epigenetic modifiers (HAC, HDAC, DNMT, list in Supplementary Fig.1c) and 
3) differential expression levels (Supplementary Fig.1b). Genes with low differential expression (Log2(MK-ESC)<1 or 
<2 with no reported interactions) were excluded from the candidate list. 
Recombinant lentiviral vectors. Transcription factor cloning. The human coding sequences of the 9 candidate genes 
(variants 1 from NCBI Reference Sequence Database) including the 5’ Kozak consensus sequence were generated by 
PCR using cbMK cDNA, individually cloned into the pWPT lentiviral vector backbone (Dr. Trono, Addgene #12255) 
downstream of the human EF1-alpha ubiquitous promoter and checked for sequence integrity. Viral particle 
production. Replication deficient lentiviral vector particles (LVPs) were produced by transient co-transfection of HEK 
293T/17 cells (ATCC CRL-11268) with pWPT constructs along with the psPAX2 and pMD2.G helper plasmids (Addgene 
#12260, #12259) using TransIT-LT1 transfection reagent (MirusBIO). Crude supernatants containing LVPs were 
concentrated by PEG-based precipitation (LentiX-concentrator, Clontech) and functional titers determined by qPCR 
measurement of provirus copy number in genomic DNA of transduced HCT116 cells (ATCC CCL-247). Human 
pluripotent stem cell transduction. hPSC lines were routinely transduced by 18-24 hours single exposure to LVPs 
using multiplicity of infection of 20 in presence of 10μg/ml Protamine Sulfate (Sigma) in routine culture medium. 
Megakaryocyte forward programming (MK-FOP). Optimised embryoid body based protocol (Fig. 2a). On 
transduction day (day 0), sub-confluent (50-80%) hPSC cultures were dissociated to single cells using TrypLE (Life 
Technologies). Embryoid body (EB) formation was initiated with 6-12E+5 viable cells per well of an Aggrewell™400 
plates (StemCell Technologies) leading to 500-1000 cells per EB following spin aggregation. Lentiviral transduction 
was performed concomitantly to the aggregation step in CDM supplemented with Y-27632 (10μM, Sigma), BMP4 
(10ng/ml, R&D) and protamine sulfate. After 24h, transduced EBs were collected and sown in ultralow adherent cell 
culture plates (Corning) at 1,200 EBs per 10cm2 dish in CDM with BMP4 and FGF2 (5ng/ml). 24 hours later, EBs were 
washed and sown in ultralow adherent plates at 600 EBs/10cm2 in CellGroSCGM medium (CellGenix) supplemented 
with TPO (100ng/ml, Cellgenix) and SCF (25ng/ml, Gibco). At day 10, EBs were dissociated to single cells using 
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Collagenase-IV and Dispase-II (1mg/ml, Gibco) followed by enzyme free cell dissociation buffer (Gibco) treatment. 
Single cells were cultivated at 2E+5/ml on tissue culture plates (Corning) for an additional 10 days in CellgroSCGM 
with TPO (100ng/ml) and IL1-β (10ng/ml, Miltenyi Biotec). Half of culture media was renewed every 3 days. Long 
term MKFOP cultures. From day 10 after dissociation to single cells, the cultures were maintained in CellGroSCGM 
with low TPO concentration (20ng/ml) and SCF (50ng/ml). Culture medium was half-renewed every 3 days and cells 
split every 7-10 days when reaching concentration of 1-1.5E+6 cells/ml. FOP-MK freezing. Cells from day 30-70 
cultures were collected and frozen at 0.5-2E+6 cells/ml in IMDM 20% Fetal Bovine Serum (Gibco) and 5% DMSO 
(Sigma).  Adherent cell protocol. Small cell clumps were generated from sub-confluent hPSC cultures using a 
Collagenase-IV and Dispase-II mix and sown on human fibronectin coated (50μg/ml, Millipore) wells in CDM 
containing FGF2 and Activin A (15ng/ml each) at an approximate density of 2-5E+5 cells/10cm2. Cells were 
transduced with LVPs the next day and kept for 2 days in FGF2+Activin A (pluripotency) or FGF2+LY-294002+BMP4 25 
(mesoderm) depending on experiment settings. From day 2, cells were maintained in CellgroSCGM with TPO and SCF 
as described above. MK directed differentiation. hPSC lines were differentiated as described 27 using batch tested 
serum and stromal cells from Prof Koji Eto laboratory. 
Cord blood derived megakaryocytes. Cord blood was obtained after informed consent under a protocol approved 
by the Cambridgeshire 4 Research Ethics Committee (07/MRE05/44). CD34-positive cells (≥98%) isolated 
by magnetic cell sorting (Myltenyi Biotec) were seeded at 1E+5 cells/ml in CellgroSCGM containing TPO (100ng/ml) 
and IL1-β (10ng/ml) and cultivated for 10 days. We routinely obtained 70-90% CD41a+ and 20-60% CD42a+ cells by 
the end of the culture. 
Flow cytometry analysis. Flow cytometry experiments were performed on a CyAn ADP (Beckman Coulter). Single cell 
suspensions were generated using a Collagenase-IV/Dispase-II mix and/or enzyme free dissociation buffer. Cells 
were stained for 20’/RT in PBS 0.5%BSA 2mM EDTA using combinations of FITC, PE and APC conjugated antibodies 
(see Supplementary Table 1). Background fluorescence was set against matched isotype control antibodies and 
compensation matrix defined using single-color stained cells. Flow count fluorospheres (Beckman Coulter) and DAPI 
(1ug/ml) were used to determine viable cell count in samples. 
Cell morphology and phenotype analysis. Cell morphology analysis. Cells were spun onto a glass slide using 
cytofunnels at 400g for 5’, methanol fixed and stained using the Romanowsky method. Megakaryocyte colony 
forming assay. 5,000 cells per chamber were used in MethoCult methylcellulose assays (#4230, StemCell 
Technologies) containing screened fetal bovine serum and supplemented with TPO and SCF (100 and 50ng/ml 
respectively); MegaCult collagen cultures (StemCell Technologies) were dehydrated following manufacturer’s 
instructions for colony immunostaining. Immunofluorescence analysis. Megakaryocytes were cultivated on human 
fibrinogen (50μg/ml, Millipore) coated glass cover slips for 48h to foster adhesion and proplatelet formation. Cells 
were fixed in 2% formaldehyde, permeabilised with 0.1% Saponin/0.2% Gelatin and incubated 2h/RT with selected 
primary antibodies (see Supplementary Table 1) then with fluorochrome conjugated secondary antibodies for 
45’/RT. Cell nuclei were stained with DAPI. Images were acquired on a fluorescent microscope Axiovert 40 (Zeiss) or 
a SP5 confocal microscope for granule imaging (Leica). Ploidy analysis. Cells were fixed using 4% formaldehyde for 
10’/RT, immunostained for CD41a and CD42a expression and subsequently incubated in PBS 0.1% Tween with DAPI 
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at 1ug/ml for 15’/RT before flow cytometry analysis. Transmission electron microscopy. Megakaryocytes were fixed 
in 2% glutaraldehyde/formaldehyde followed by post-fixation, resin embedding and staining as previously described 
17,64, and eventually analysed on a FEI Tecnai G2 microscope.  
Gene expression analysis by RT-qPCR. Total RNA was extracted using RNeasy kits (Qiagen) according to the 
manufacturer’s instructions including DNase treatment. cDNA was prepared from 250-500ng total RNA using 
Maxima First Strand cDNA Synthesis Kit (random hexamers and oligo(dT)18 mix for priming; Fermentas). Two-step 
qPCR reactions were performed in duplicates using SYBR green chemistry on ABI 7500HT or Mx3000P instruments 
(Applied Biosystems; Agilent Technologies). Relative gene expression was calculated by the 2-Δct method using HMBS 
as housekeeping gene for normalisation. qPCR primer pairs (Supplementary Table 2) designed to amplify only cDNA, 
to detect all known isoforms, and to have no reported off-target matches searching the human NCBI RefSeq 
database were tested within 80-120% PCR efficiencies with single dissociation curves. We used UTR targeting 
(absent from transgenes) to monitor endogene expression while transgene specific primer pairs used a common 
reverse primer specific to the viral vector RNA. 
Whole genome expression microarray analysis. DNA free total RNA was extracted as above from sorted CD42b+ cell 
fractions using the EasySep system (Stemcell Technologies; >95% purity, for cbMK, ddMK and fopMK samples) or 
unsorted >80% CD42b+ cells (LT-fopMK samples) and 500ng hybridised to Illumina Human HT-12 v4 BeadArrays. 
Microarray Gene Expression. Microarray signal intensities from Genome Studio version1.9 were variance stabilisation 
transformed and robust spline normalised (RSN).  For differential analysis, we removed low signal probes with 
detection P-value>0.01 in all samples, leaving only informative probes. These procedures were carried out using R 
package Lumi. For each pairwise differential analysis, we applied surrogate variable analysis (SVA) to correct for un-
modelled factors that may bring about batch effects. We then tested for differential expression using limma where 
statistical significance was set to 2-fold change and 5% false discovery rate or Benjamini-Hochberg adjusted P-value. 
Hierarchical clustering. Hierarchical clustering was performed using R package pvclust.  For dissimilarity or distance 
measure, we use 1-correlation and average as agglomerative method. Gene Ontology Enrichment Analysis. We 
performed enrichment analysis using GOstat 2.24 of over-represented gene ontology (GO) terms in the set of 
differentially expressed genes. We used standard hypergeometric test using only informative probes in the chip as 
the universe. Gene Set Enrichment Analysis (GSEA). We used gsea2-2.0.13 with datasets for megakaryocytes (n=4) 
and other blood cells (n=46) from the Haematlas study 23 (E-TABM-633; Illumina Human-6v2 array). Principal 
Component Analysis. Classification of samples in multiple dimensional factor spaces was applied by calling the 
function cmdscale.  Gene expression heatmaps. Heatmap builder v1.1 (Dr Ashley lab, Stanford) was used for dataset 
normalised representations.   
In vitro platelet analysis. Co-culture on feeder cells. To promote platelet production, day 10 cbMKs and day 20-90 
fopMKs were further cultivated for 48h in CellgroSCGM plus Heparin (25U/ml) without further cytokine addition at 
1E+5 cells/cm2 on gamma-irradiated C3H10T1/2 feeder cells (Riken Institute; 1E+4 cells/cm2). Platelet flow analysis. 
Crude supernatant containing the platelets was analysed by flow cytometry after addition of 1:9 volume of acid 
citrate dextrose (ACD, Sigma) and cell removal by centrifugation 150g/10’. Antibodies against human platelet 
receptors were added directly to the media (1:50 dilution, see Supplementary Table 1) for 30’/RT and unwashed 
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platelets analysed using fluorospheres for quantification. Human platelets from fresh whole blood diluted in 
PBS/ACD or from day 8-10 platelet concentrate units (NHSBT, UK) were analysed in parallel. Washed platelet 
preparation. Human platelet rich plasma (PRP) and in vitro generated platelets collected as above were washed 
following the optimised protocol from Cazenave et al. 65 to prevent activation and maximise platelet function 
preservation. Platelet size analysis. Washed platelets were run on a Sysmex XE-2100™ Automated Hematology 
System. Electron microscopy. Washed platelets were fixed and stained as described for MKs. Spreading assay. 
Washed platelets in Tyrode-HEPES buffer complemented with CaCl2 1mM were sown on fibronectin coated glass 
cover slips and incubated 45’/37°C. They were subsequently fixed using 2% formaldehyde, immunostained and 
analysed as described for MKs. Platelet survival in vivo. Washed platelets were injected to macrophage depleted (by 
clodronate liposome injection at day -3) 8-12 week-old male NOD scid gamma (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ; 
NSG) mice through the tail vein as single dose of 2E+7 CD41a/42a++ platelets. The human versus mouse platelet 
content was monitored by flow cytometry from whole blood samples at 1, 30, 120 minutes and 24 hours after 
transfusion using antibodies specific for human and murine CD41a. The absolute human platelet count was 
determined using flow count fluorosphere (Beckman Coulter) and platelet survival calculated by the multiple hits 
method relative to the 30 minutes equilibrium time point 66,67. All mice were kept in specific pathogen-free 
conditions, and all procedures were performed according to the United Kingdom Home Office regulations and 
approved by the University of Cambridge Animal Welfare Ethical Review Body. In vitro thrombus formation in 
laminar flow. Human blood or in vitro platelets were stained with Calcein-AM (100nM; Life Technologies) for 10’ at 
37°C before being washed and defined amount were mixed with 1ml of human blood collected in 3.2% Citrate. 
Thrombocytopenic blood was artificially prepared by depleting the platelets from plasma by performing 2 sequential 
centrifugation steps at 2,200g for 10’ and washing the red blood cell fraction with Tyrode-HEPES buffer before blood 
reconstitution. The procedure for clot formation under flow was modified from de Witt et al. 68. Briefly, glass slides 
were locally coated with Horm collagen spots (50μg/ml) and mounted into a flow chamber placed under a 
fluorescent microscope (EVOS system, Advanced Microscopy Group). The blood was then perfused through the 
chamber at 1600s-1 (7.2ml/hr) for 3 minutes allowing thrombi formation on collagen spots and imaging subsequently 
performed. Image analysis was carried on using ImageJ recording thrombus area and calcein-AM events per clot. 
Thrombus formation intravital imaging. Washed platelets were labelled with Calcein-AM and injected to 
macrophage depleted 8-12 week-old male NSG mice through the carotid artery after cannulation as single dose of 
5E+7 CD41a/42a/CalceinAM+++ platelets. Thrombus formation was induced from 15 minutes onwards after platelet 
transfusion by micropoint laser injury of the cremaster vessel walls as previously described 39. Fluorescent and bright 
fields were simultaneously recorded by confocal microscopy and analysed using SlideBook 6 (Intelligent Imaging 
Innovations). The number of Calcein-AM+ human platelets incorporated in mouse thrombi until maximal size was 
reached was recorded and reported to thrombus area. All animal experiments have been approved by the United 
Kingdom Home Office and the Birmingham University Animal Welfare Ethical Review Body. Flow cytometry 
Aggregation assay. Modified from original protocol 38 to include the live–dead particle discriminator Calcein–AM, it 
allows quantification of platelet aggregation using small numbers of platelets (2E+6 per reaction). Duplicate platelet 
samples were stained with Calcein–AM and anti-CD31 (clone WM59) conjugated with APC or V450 in HEPES buffer 
supplemented with 20µM PPACK dihydrochloride (Calbiochem), washed then mixed in the presence or absence of 
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the agonists Thrombin receptor activating peptide (TRAP) and ADP (10µM each). Percentage aggregation was 
determined by flow cytometry for Calcein-AM positive double CD31 positive events. Bead platelet adhesion flow 
cytometry assay. Modified from original protocol 36, it quantifies adhesion of platelets to single 20µM polystyrene 
beads (Sigma) coated with either BSA or Fibrinogen. 3 x 10^5 platelets stained with 100nM Calcein-AM  were mixed 
in basal culture media with either 20µl BSA or 20µl fibrinogen coated beads, agonists (TRAP and ADP as above), 
incubated for 10’/37°C and subsequently stained with anti-CD41a-APC antibody. DAPI negative, Calcein-AM and 
CD41a positive single beads bound by platelets are quantified by flow cytometry. 
Statistics. Results are presented as mean ± standard error of the mean (sem) with n representing the number of 
biological replicates unless otherwise stated. Statistical P values were calculated by 2-tail Student’s t-test unless 
otherwise stated.  
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FIGURE LEGENDS 
Figure 1. TF candidate screening for MK forward programming. (a) TF expression in hPSCs vs. cbMKs plotted as a 
row normalized heatmap with indications of recorded TF internal and chromatin modifiers node numbers and 
protein interactions among the top 20 TF candidates reported by VisANT.  The 9 experimentally tested TFs are 
highlighted in red. (b) The H9 hESC line was concurrently transduced with the 9-TFs and maintained in pluripotency 
medium (FGF2+activin-A) for 2 days followed by MK medium (TPO+SCF) for a further 5 days. CD41a+ cells generated 
7 days after lentiviral transduction (dot plot, mean% ±sem, n=5; FL1: 530/40nm channel) were sorted by flow 
cytometry and transgene expression levels quantified by RT-qPCR (n=1). (c) The percentage of CD41a+ cells was 
monitored by flow cytometry 7 days after transduction of the hiPSC lines #1 and #2 with the 9-TFs or 3-TFs 
combination. Bar graphs represent the fold increase of CD41a+ cell count relative to the 9-TFs combination (mean 
±sem, n=4; ** P<0.01 by 2-tail T-test). NT: non transduced cells. (d) The hiPSC#1 line was transduced with all 
permutations of the 3-TFs and percentages of CD41a+ cells measured by flow cytometry at day 7. Bar graphs 
represent the fold increase of CD41a+ cell count relative to the 3-TFs combination (mean ±sd, n=2; * P=0.06 and 
P<0.01 vs. G+F and other combination respectively by 2-tail T-test). G: GATA1, F: FLI1, T: TAL1, GFP: control vector. 
(e) The endogenous expression of key MK genes was monitored by RT-qPCR from CD41a flow sorted cells 7 days 
after transduction of the hiPSC lines #1 and #2 (mean ±sd, n=2). (f) The hiPSC lines #1 and #2 were transduced with 
the 3-TFs and sorted by flow cytometry for expression of CD41a at day 7. The clonogenic potential of sorted cells was 
tested in methylcellulose semi-solid medium supplemented with TPO and SCF. The number of colonies per 5,000 
sown cells was determined after 10 days from duplicate wells (mean ±sem, n=4). (g) A representative MK colony 
obtained from a CD41a+ cell co-expressing CD41a and CD42b as detected by immunofluorescence is shown (scale 
bar 50μm).   
Figure 2. Generation of mature MKs by forward programming using chemically defined conditions. (a) Schematic 
representation of the optimized MK-FOP protocol. Viral transduction at day 0 concurrent with embryoid body 
generation and mesoderm induction for 2 days was followed by a period of culture in an MK induction medium 
(TPO+SCF) for 8 days. Embryoid bodies showing cystic structures and actively growing cell aggregates were 
dissociated to single cells at day 10 and further differentiated to mature MKs (TPO+IL1β) until day 20 post 
transduction. (b) Time course of fopMK differentiation showing MK lineage commitment (%CD41a+ cells) and MK 
maturation (%CD42a+ cells) from whole culture (mean ±sem from hiPSC lines #1 and #2; n=2 (day0-10); n=6 (day14-
22)). Representative flow cytometry dot plots for CD41a and CD42a expression are shown below. (c) The MK fold 
increase at day 20 relative to the day 0 hiPSC input is shown on a logarithmic scale for the hiPSC lines #1-4 
differentiated by forward programming (fopMK: mean ±sem; n=14, 7, 3, 5 respectively) or directed differentiation 
(hiPSCs#1 and #2; ddMK: mean ±sem; n=3,2 respectively). **P<0.01 and *P<0.05 by 2-tail T-test. (d) Representative 
histograms of the expression of major platelet receptors detected by flow cytometry are shown for day 20 fopMKs 
(red line) and day 10 cbMKs (blue line) against isotype control (grey shade). (e) The morphology of day 20 fopMKs 
and day 10 cbMKs was analyzed by modified Romanowsky staining on fixed cells. Arrowheads point to 
multinucleated cells. Scale bars 25μm. (f) Cell size distribution from fopMK and cbMK cultures is shown as box plots: 
center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the 
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interquartile range from the 25th and 75th percentiles, outliers are represented by dots (n=50, 74 respectively; 
**P<0.01 by 2-tail T-test). (g) Cell ultrastructure of fopMKs and cbMKs was visualized by transmission electron 
microscopy. dms: demarcation membrane system; gr: granules; mvb: multivesicular body; mit: mitochondria. Scale 
bars, 2μm. (h) Representative confocal pictures of fopMKs immunostained for major alpha-granule proteins 
(thrombospondin, fibrinogen, P-selectin and Von Willebrand Factor; iPSC#3 fopMKs, day 40). Scale bars 25μm. 
Figure 3. Long-term expansion of fopMKs. (a) Schematic representation of the culture conditions for long term MK-
FOP. The combination of TPO (20ng/ml) and SCF (50ng/ml) allowed mature MK expansion for 90 days and beyond. 
(b) The cumulative mature MK (CD41a/CD42a double positive cells) fold increase relative to day 0 hiPSC cell input is 
shown for the hiPSC lines #1 (n=4) and #3 (n=5) over 90 days in culture (mean ±sem). (c-d) The corresponding 
percentages of CD41a+ and CD42a+ cells monitored by flow cytometry from whole cultures are shown over the 90 
day period (mean ±sem). (e) Representative flow cytometry dot plots for CD41a and CD42a expression from the 
hiPSC#3 line. (f-g) Representative phase contrast picture of a day 70 hiPSC#3 fopMK long term culture and 
associated Romanowsky staining of fixed cells. White arrowheads: clumps of actively growing small cells; red 
arrowheads: single big cells in suspension culture and polyploid cells identified by Romanowsky staining. (h) Cell size 
distribution from fopMK and LT-fopMK cultures is shown as box plots (n=50, 65 respectively). (i) Endogenous and 
transgenic expression levels of the 3-TFs were independently monitored by RT-qPCR throughout MK-FOP long term 
cultures (mean ±sem from hiPSC lines #1 and #3; n=3). The average range of expression levels in cbMKs (mean ±sem; 
n=5) is shown as a benchmark (in red).  
Figure 4. Transcriptional landscape of forward programmed MKs. The undifferentiated hiPSC#1 line (n=2), day 20 
fopMKs (hiPSC#1-2, n=4,2), day 25 ddMKs (hiPSC#1, n=4), day 10 cbMKs (n=4; all three groups CD42b+ sorted >95%) 
and day 30-69 LT-fopMKs (hiPSC#1 and #3, n=8 and 6; >80% CD42b+), were analyzed for gene expression using 
Illumina Human HT-12 v4 BeadArrays. (a) Top five enriched gene ontology biological processes for differentially 
expressed (DE) genes in all MK samples compared to hiPSCs. –Log10 P-values are shown as color scale. (b) Gene set 
enrichment analyses for DE genes from the different MK samples (vs. hiPSCs; grey circles) against a “MK vs. other 
blood types” gene expression dataset (from Haematlas 23). NES: Normalized Enrichment Score; FDR: False Discovery 
Rate. (c) Gene expression correlation scatter plots on the whole gene set using pairwise comparisons of different MK 
groups. R2 Pearson correlation value and differentially expressed gene numbers are indicated. The differential 
expression threshold (2 fold-change; FDR 5%) is shown as dotted red lines. (d) Venn diagrams recording DE genes 
(|Log2 fold-change| >1; FDR5%) in hiPSC derived MKs compared to cbMKs. The number of DE genes is indicated for 
each intersection and the top five enriched GO term biological processes from the Venn Diagram intersections are 
shown.  (e) Hierarchical clustering using the average agglomerative method on whole gene dataset. (f) Three 
dimensional plots of the Principal Component (PC) Analysis of MK populations. The first 3 PC are shown with 
respective percentages of variance indicated in brackets. The two PCA boxes are snapshots of a rotation along the 
PC3 axis with MK sample groups highlighted. 
Figure 5. Platelet release in vitro from fopMKs throughout long term culture. (a) Phase contrast picture of 
spontaneous proplatelet-forming fopMKs (arrowheads) in suspension culture (hiPSC#3, day26; scale bar 50μm). (b) 
Proplatelet-forming fopMK on fibrinogen-coated slide immunostained for alpha-tubulin (TUBA) and P-selectin (SELP). 
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Arrowheads indicate nascent platelet tips containing SELP positive granules (hiPSC#4, day21; scale bar 50μm). (c) 
Transmission electron microscopy pictures of blood and in vitro-produced platelets showing typical ultrastructure. 
AG: alpha-granules; MVB: multi vesicular bodies (scale bars 1μm). (d) Representative flow cytometry dot plots of 
platelet analysis. Platelets are defined within the human platelet size gate as CD41a/CD42a double positive events. 
(e) cbMK and fopMK from different culture time points were sown on C3H10T1/2 feeder cells for 48 hours and the 
number of platelets released in the supernatant quantified by flow cytometry. Data represent the mean ±sem of 
platelet number per MK sown (n=7, 4, 10, 6, 2 for cbMK and fopMK (hiPSC#1-4 pool) at day 20-90 respectively; 
**P<0.01 vs. fopMK day 20 by 2-tail T-test). (f-g) Mean platelet volume (MPV) ±sd and immature platelet fraction 
(IPF) ±sd of washed donor and fopMK platelets as measured on a Sysmex whole blood analyzer (n=4/2 respectively; 
hiPSC#1 and #5). (h) Human platelet survival in NSG mice circulation over 24 hours measured by flow cytometry 
following the systemic injection of 20 million washed platelets. The exponential trend of human platelet absolute 
count decrease over time was used for half-life calculation (mean ±sem; n=5/4 for donor and fopMK (hiPSC#1 and 
#5) platelets respectively). 
Figure 6. Functional assessment of fopMK in vitro platelets. (a) Adhesion to fibrinogen of fopMK and cbMK in vitro 
platelets upon combined TRAP+ADP stimulation compared to blood platelets using a flow cytometry bead based 
assay. Percentages of adhesion on BSA or fibrinogen coated beads are shown (mean ±sem, n=4, 4, 2 for blood, 
fopMK and cbMK respectively; **P<0.01 vs. blood by 2-tail T-test). (b) Representative pictures from in vitro 
spreading assay. Washed platelets were sown on fibrinogen coated slides, incubated for 45’ at 37°C and 
immunostained for alpha-tubulin (TUBA) and F-actin (scale bars 10μm). (c) Aggregation of fopMK platelets upon 
agonists stimulation was tested both with and compared to blood platelets using a flow cytometry-based assay: 
representative dot plots are shown. (d) Percentages of aggregation from Calcein-AM+ live platelets upon stimulation 
are shown for blood and fopMK platelets reactions (2x107 platelets/ml; mean ±sem, n=7 for each reaction group; no 
statistical difference vs. blood at P<0.01 by 2-tail T-test). (e) Associated delta-aggregation defined as ((% ADP+TRAP 
aggregation) – (% no agonist aggregation)) for the different reaction groups (mean ±sem, n=7; P-values by 2-tail T-
test  vs. blood indicated). (f) Thrombus formation in vitro under arterial shear stress. The participation of Calcein-AM 
live platelets spiked into human blood (at 1x107/ml) is shown per 100μm2 thrombus area. Normal or 
thrombocytopenic blood (>150x109 and <50x109L-1 respectively) was used as recipient. Spiked platelets were 
sourced from day-8 concentrate unit (blood) or from fopMK platelets (iPSC#1 and #5; n>30 analyzed thrombi per 
group; P-values by 2-tail T-test vs. blood indicated). (g) Representative pictures from in vitro thrombus formation 
assays. Thrombi identified using bright field images are delineated and Calcein-AM platelets fluorescing in green; in 
vitro platelets Calcein-AM labelling is intrinsically dimmer than donor-derived platelets (Supplementary Fig. 5b). 
Scale bar 50μm. (h) Thrombus formation in vivo by laser injury of an arteriole in the cremaster muscle of NSG mice 
and intravital confocal microscopy. The incorporation of human Calcein-AM labelled platelets (50 million transfused 
per mouse) to mouse thrombi is shown per 100μm2 thrombus area at T_max (thrombus maximum size). Mean 
values ±sem and P-values by 2-tail T-test vs. donor platelets are shown (n=16/4/8 thrombi analyzed for blood, 
fopMK#1 and #5 platelets respectively). (i) Representative snapshots of Calcein-AM+ human platelets incorporated 
to mouse thrombus. 
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